. 2019 Apr 4;10(5):283–295. doi: 10.3892/br.2019.1204

Table VII.

Daily glibenclamide dosage stratified in accordance with IVS8-109A>T (CYP2C9) genotypes determined in the present study.

	Glibenclamide daily dosage (mg) and dosage/body weight (mg/kg)
	CYP2C9 (IVS8-109A>T) genotypes
Oral hypoglycemiant	A/A (n)	A/T (n)	T/T (n)
Glibenclamide (n=10)	10.000(6)^a [5.500-15.000]	2.500(3)^a [2.500-3.750]^b	10.000(1)^a
	0.148(6)^a [0.110-0.190]	0.039(3)^a [0.038-0.062]^b	0.148(1)^a
Glibenclamide (glibenclamide/ metformin group) (n=97)	15.000(74)^a	13.750(20)^a	15.000(3)^a
	[10.000-15.000]^c	[10.000-15.000]^c	[12.500-15.000]
	0.193(74)^a	0.170(20)^a	0.180(3)^a
	[0.130-0.230]	[0.130-0.260]^c	[0.140-0.240]
Metformin (glibenclamide/metformin group) (n=97)	1,700(74)^a	1,700(20)^a	2,550(3)^a
	[1,275-2,550]	[850-2,550]	[1,275-2,550]
	27.370(74)^a	31.870(20)^a	31.480(3)^a
	[19.140-37.780]	[20.860-36.960]	[18.050-39.790]

Data are expressed as ^a = median; [-] = IQR (interquartile range); n, number of individuals;

^bP<0.05 (genotypes);

^cP<0.05 (oral hypoglycemiant). CYP2C9, cytochrome P450 2C9.